Mirtazapine description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Mirtazapine

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING


Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.  Anyone considering the use of mirtazapine orally disintegrating tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Mirtazapine is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)

DESCRIPTION


17193




CLINICAL PHARMACOLOGY




2

2 31A1B

1

1







In vitro





GERIATRIC USE


PRECAUTIONS DOSAGE AND ADMINISTRATION

CLINICAL PHARMACOLOGYDOSAGE AND ADMINISTRATION

CLINICAL STUDIES







INDICATIONS & USAGE





CLINICAL PHARMACOLOGY





CLINICAL PHARMACOLOGY

CONTRAINDICATIONS


WARNINGS




 




All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.






Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers.
 

PRECAUTIONS


Information for Patients

PRECAUTIONS: Pediatric Use

CLINICAL PHARMACOLOGYDOSAGE AND ADMINISTRATION






22CLINICAL PHARMACOLOGYDOSAGE AND ADMINISTRATION

INFORMATION FOR PATIENTS













CLINICAL PHARMACOLOGY

In vitroin vitro



2


in vitro in vitro in vivo
2

PREGNANCY


Pregnancy Category C

22

NURSING MOTHERS




PEDIATRIC USE





PRECAUTIONS-Increased Appetite/Weight Gain

ADVERSE REACTIONS




















WARNINGSPRECAUTIONS
Body as a Whole:frequent:infrequent: rare:

Cardiovascular System:frequent: infrequent:rare:

Digestive System:frequent: infrequent: rare:

Endocrine System:rare:

Hemic and Lymphatic System: rare:

Metabolic and Nutritional Disorders:frequent: infrequent: rare:

Musculoskeletal System:frequent: infrequent:rare:

Nervous System:frequent: infrequent: rare:

Respiratory System:frequent: infrequent: rare:

Skin and Appendages:frequent: infrequent: rare:

Special Senses:infrequent: rare:

Urogenital System:frequent:infrequent: rare:




DRUG ABUSE AND DEPENDENCE







OVERDOSAGE









Physicians’ Desk Reference (


DOSAGE & ADMINISTRATION




PRECAUTIONSCLINICAL PHARMACOLOGY
CLINICAL PHARMACOLOGY

HOW SUPPLIED





15 mg Tablets –








30 mg Tablets –







45 mg Tablets –






Storage
 


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL














MirtazapineMirtazapine

Mirtazapine

Mirtazapine TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-012(NDC:65862-032)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MIRTAZAPINE Mirtazapine 45 mg

Inactive Ingredients

Ingredient Name Strength
MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
MAGNESIUM STEARATE
HYDRATED SILICA
lactose monohydrate
HYPROMELLOSE 2910 (6 MPA.S)
hydroxypropyl cellulose

Product Characteristics

Color Size Imprint Code Shape
white 14 mm 10;A OVAL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-012-02 30 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA076921 2010-09-13


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.